211 related articles for article (PubMed ID: 19327621)
1. Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?
Cohn J; Cleland JG; Lubsen J; Borer JS; Steg PG; Perelman M; Zannad F
J Card Fail; 2009 Apr; 15(3):199-205. PubMed ID: 19327621
[TBL] [Abstract][Full Text] [Related]
2. Keeping apples and oranges separate: reassessing clinical trials that use composite end points as their primary outcome.
Chan PS; Nallamothu BK; Hayward RA
J Am Coll Cardiol; 2006 Aug; 48(4):850; author reply 851-2. PubMed ID: 16904570
[No Abstract] [Full Text] [Related]
3. Key issues in end point selection for heart failure trials: composite end points.
Neaton JD; Gray G; Zuckerman BD; Konstam MA
J Card Fail; 2005 Oct; 11(8):567-75. PubMed ID: 16230258
[TBL] [Abstract][Full Text] [Related]
4. The evaluation of the results of clinical trials: surrogate end points and composite end points.
Gensini GF; Conti AA
Minerva Med; 2004 Feb; 95(1):71-5. PubMed ID: 15041928
[TBL] [Abstract][Full Text] [Related]
5. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
Heinz J; Kropf S; Luley C; Dierkes J
Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
[TBL] [Abstract][Full Text] [Related]
6. A global ranking approach to end points in trials of mechanical circulatory support devices.
Felker GM; Anstrom KJ; Rogers JG
J Card Fail; 2008 Jun; 14(5):368-72. PubMed ID: 18514927
[TBL] [Abstract][Full Text] [Related]
7. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
Powers JH
Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
[TBL] [Abstract][Full Text] [Related]
8. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus.
Gordon C; Bertsias G; Ioannidis JP; Boletis J; Bombardieri S; Cervera R; Dostál C; Font J; Gilboe IM; Houssiau F; Huizinga TW; Isenberg D; Kallenberg CG; Khamashta MA; Piette JC; Schneider M; Smolen JS; Sturfelt G; Tincani A; Van Vollenhoven R; Boumpas DT
Ann Rheum Dis; 2009 Apr; 68(4):470-6. PubMed ID: 18388158
[TBL] [Abstract][Full Text] [Related]
9. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
Lonn E
Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome measures of specific immunotherapy.
Pfaar O; Anders C; Klimek L
Curr Opin Allergy Clin Immunol; 2009 Jun; 9(3):208-13. PubMed ID: 19365259
[TBL] [Abstract][Full Text] [Related]
11. Measurement of end points in heart failure trials: jousting at windmills?
Hauptman PJ
Mt Sinai J Med; 2004 Oct; 71(5):298-304. PubMed ID: 15543430
[TBL] [Abstract][Full Text] [Related]
12. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
Calvert AH; Plummer R
Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
[TBL] [Abstract][Full Text] [Related]
13. [From clinical trials to routine treatment. General aspects of clinical trials in cardiovascular diseases].
Reikvam A
Tidsskr Nor Laegeforen; 1994 Feb; 114(4):455-8. PubMed ID: 8009484
[TBL] [Abstract][Full Text] [Related]
14. [Composite endpoints in clinical trials].
Ferreira-González I; Alonso-Coello P; Solà I; Pacheco-Huergo V; Domingo-Salvany A; Alonso J; Montori V; Permanyer-Miralda G
Rev Esp Cardiol; 2008 Mar; 61(3):283-90. PubMed ID: 18361902
[TBL] [Abstract][Full Text] [Related]
15. Improving the quality of care for women with cardiovascular disease: report of a DCRI Think Tank, March 8 to 9, 2007.
Berger JS; Bairey-Merz CN; Redberg RF; Douglas PS;
Am Heart J; 2008 Nov; 156(5):816-25, 825.e1. PubMed ID: 19061693
[TBL] [Abstract][Full Text] [Related]
16. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial).
Boden WE; O'Rourke RA; Teo KK; Maron DJ; Hartigan PM; Sedlis SP; Dada M; Labedi M; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
Am J Cardiol; 2009 Jul; 104(1):1-4. PubMed ID: 19576311
[TBL] [Abstract][Full Text] [Related]
17. Evaluating pathophysiologic processes rather than clinical end points in improving therapeutic practice.
Cohn JN
J Cardiovasc Pharmacol; 1998; 32 Suppl 3():S38-40. PubMed ID: 9883746
[TBL] [Abstract][Full Text] [Related]
18. End points for cardiovascular drug trials in pediatric patients.
Sinaiko AR; Lauer RM; Sanders SP
Am Heart J; 2001 Aug; 142(2):229-32. PubMed ID: 11479459
[No Abstract] [Full Text] [Related]
19. End points for phase II trials in intensive care: recommendations from the Australian and New Zealand Clinical Trials Group consensus panel meeting.
Young P; Hodgson C; Dulhunty J; Saxena M; Bailey M; Bellomo R; Davies A; Finfer S; Kruger P; Lipman J; Myburgh J; Peake S; Seppelt I; Streat S; Tate R; Webb S;
Crit Care Resusc; 2012 Sep; 14(3):211-5. PubMed ID: 22963216
[TBL] [Abstract][Full Text] [Related]
20. Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute.
Douglas PS; Taylor A; Bild D; Bonow R; Greenland P; Lauer M; Peacock F; Udelson J
J Cardiovasc Comput Tomogr; 2009; 3(4):212-23. PubMed ID: 19577208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
